Congestive Heart Failure and Thyroid Dysfunction: The Role of the Low T3 Syndrome and Therapeutic Aspects

Author(s): Giuseppe Lisco, Anna De Tullio, Massimo Iacoviello, Vincenzo Triggiani*

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 20 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Both the morbidity and mortality rates from congestive heart failure (CHF) remain elevated despite the medical and non-medical management of the disease, thus suggesting the existence of residual risk factors such as thyroid dysfunction. Particularly, the 15-30% of patients with CHF, especially those with severe ventricular dysfunction, display the so-called low T3 syndrome (LT3S), which seems to negatively affect the cardiovascular prognosis.

Objective: Only a few clinical trials have been carried out to verify both the safety and the efficacy of thyroid replacement in the LT3S, aiming to ameliorate the prognosis of CHF, and most of the results were controversial.

Methods: Since the aim of the present review was to briefly overview both the indication and contraindication of triiodothyronine replacement in CHF and LT3S, the authors searched PubMed using the medical subject headings (MeSH) related to the following terms: “congestive heart failure” and “low T3 syndrome” or “euthyroid sick syndrome” or “non-thyroidal sick syndrome”. The research study only focused on the narrative and systematic reviews, randomized clinical trials and meta-analysis studies which were conducted before June 2019.

Results: Studies conducted in both animal models and humans provided controversial information about the effectiveness and safety of the T3 replacement for improving ventricular dysfunction, particularly in the long-term.

Conclusion: Further clinical trials are needed to better explore the role of LT3S in patients with CHF and its consequent therapeutic strategy in this clinical setting.

Keywords: Hypothyroidism, low T3 syndrome, euthyroid sick syndrome, non-thyroidal sick syndrome, congestive heart failure, levothyroxine, liothyronine, selenium.

[1]
Ziaeian, B.; Fonarow, G.C. Epidemiology and aetiology of heart failure. Nat. Rev. Cardiol., 2016, 13(6), 368-378.
[http://dx.doi.org/10.1038/nrcardio.2016.25] [PMID: 26935038]
[2]
Mozaffarian, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; Das, S.R.; de Ferranti, S.; Després, J.P.; Fullerton, H.J.; Howard, V.J.; Huffman, M.D.; Isasi, C.R.; Jiménez, M.C.; Judd, S.E.; Kissela, B.M.; Lichtman, J.H.; Lisabeth, L.D.; Liu, S.; Mackey, R.H.; Magid, D.J.; McGuire, D.K.; Mohler, E.R., III; Moy, C.S.; Muntner, P.; Mussolino, M.E.; Nasir, K.; Neumar, R.W.; Nichol, G.; Palaniappan, L.; Pandey, D.K.; Reeves, M.J.; Rodriguez, C.J.; Rosamond, W.; Sorlie, P.D.; Stein, J.; Towfighi, A.; Turan, T.N.; Virani, S.S.; Woo, D.; Yeh, R.W.; Turner, M.B. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation, 2016, 133(4), e38-e360.
[http://dx.doi.org/10.1161/CIR.0000000000000350] [PMID: 26673558]
[3]
Zarrinkoub, R.; Wettermark, B.; Wändell, P.; Mejhert, M.; Szulkin, R.; Ljunggren, G.; Kahan, T. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur. J. Heart Fail., 2013, 15(9), 995-1002.
[http://dx.doi.org/10.1093/eurjhf/hft064] [PMID: 23645498]
[4]
Maggioni, A.P. Epidemiology of Heart Failure in Europe. Heart Fail. Clin., 2015, 11(4), 625-635.
[http://dx.doi.org/10.1016/j.hfc.2015.07.015] [PMID: 26462102]
[5]
Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy. Acta Pol. Pharm. -. Drug Res., 2011, 68, 307-316.
[6]
Ceia, F.; Fonseca, C.; Mota, T.; Morais, H.; Matias, F.; de Sousa, A.; Oliveira, A. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail., 2002, 4(4), 531-539.
[http://dx.doi.org/10.1016/S1388-9842(02)00034-X] [PMID: 12167394]
[7]
van Riet, E.E.S.; Hoes, A.W.; Wagenaar, K.P.; Limburg, A.; Landman, M.A.; Rutten, F.H. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur. J. Heart Fail., 2016, 18(3), 242-252.
[http://dx.doi.org/10.1002/ejhf.483] [PMID: 26727047]
[8]
Metra, M.; Teerlink, J.R. Heart failure. Lancet, 2017, 390(10106), 1981-1995.
[http://dx.doi.org/10.1016/S0140-6736(17)31071-1] [PMID: 28460827]
[9]
Dharmarajan, K.; Rich, M.W. Epidemiology, Pathophysiology, and Prognosis of Heart Failure in Older Adults. Heart Fail. Clin., 2017, 13(3), 417-426.
[http://dx.doi.org/10.1016/j.hfc.2017.02.001] [PMID: 28602363]
[10]
Pergola, G. Obesity and Heart Failure. Endocrine, Metab Immune Disord. Targets,, 2013, 13, 51-57.
[http://dx.doi.org/10.2174/1871530311313010007]
[11]
Triggiani, V.; Guastamacchia, E.; Giagulli, V.A.; Iacoviello, M.; De Pergola, G. Testosterone Deficiency in Male: A Risk Factor for Heart Failure. Endocrine, Metab. Immune Disord. Targets, 2013, 13, 92-99.
[http://dx.doi.org/10.2174/1871530311313010011]
[12]
Giagulli, V.A.; Guastamacchia, E.; De Pergola, G.; Iacoviello, M.; Triggiani, V. Testosterone deficiency in male: a risk factor for heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 92-99.
[http://dx.doi.org/10.2174/1871530311313010011] [PMID: 23369141]
[13]
Aroor, A.R.; Mandavia, C.H.; Sowers, J.R. Insulin resistance and heart failure: molecular mechanisms. Heart Fail. Clin., 2012, 8(4), 609-617.
[http://dx.doi.org/10.1016/j.hfc.2012.06.005] [PMID: 22999243]
[14]
Jankowska, E.A.; Biel, B.; Majda, J.; Szklarska, A.; Lopuszanska, M.; Medras, M.; Anker, S.D.; Banasiak, W.; Poole-Wilson, P.A.; Ponikowski, P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation, 2006, 114(17), 1829-1837.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.649426] [PMID: 17030678]
[15]
Salter, D.R.; Dyke, C.M.; Wechsler, A.S. Triiodothyronine (T3) and cardiovascular therapeutics: a review. J. Card. Surg., 1992, 7(4), 363-374.
[http://dx.doi.org/10.1111/j.1540-8191.1992.tb01029.x] [PMID: 1482831]
[16]
Klein, I.; Danzi, S. Thyroid disease and the heart. Circulation, 2007, 116(15), 1725-1735.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.678326] [PMID: 17923583]
[17]
Rizzo, C.; Gioia, M. I.; Parisi, G.; Triggiani, V.; Iacoviello, M. Dysthyroidism and Chronic Heart Failure: Pathophysiological Mechanisms and Therapeutic Approaches., 2017, 239-253.
[18]
AlGhalayini, K. Prevalence of hypothyroidism in a cohort of Saudi women with heart failure and effect on systolic and diastolic function. J. Pak. Med. Assoc., 2015, 65(12), 1300-1304.
[PMID: 26627511]
[19]
Kannan, L. Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circ Heart Fail, 2018, 11
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005266]
[20]
Ning, N.; Gao, D.; Triggiani, V.; Iacoviello, M.; Mitchell, J.E.; Ma, R.; Zhang, Y.; Kou, H. Prognostic Role of Hypothyroidism in Heart Failure: A Meta-Analysis. Medicine (Baltimore), 2015, 94(30)e1159
[http://dx.doi.org/10.1097/MD.0000000000001159] [PMID: 26222845]
[21]
Triggiani, V.; Iacoviello, M. Thyroid disorders in chronic heart failure: from prognostic set-up to therapeutic management. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 22-37.
[http://dx.doi.org/10.2174/1871530311313010005] [PMID: 23369135]
[22]
Ro, K.; Yuen, A.D.; Du, L.; Ro, C.C.; Seger, C.; Yeh, M.W.; Leung, A.M.; Rhee, C.M. Impact of Hypothyroidism and Heart Failure on Hospitalization Risk. Thyroid, 2018, 28(9), 1094-1100.
[http://dx.doi.org/10.1089/thy.2017.0362] [PMID: 29897016]
[23]
Chen, S.; Shauer, A.; Zwas, D.R.; Lotan, C.; Keren, A.; Gotsman, I. The effect of thyroid function on clinical outcome in patients with heart failure. Eur. J. Heart Fail., 2014, 16(2), 217-226.
[http://dx.doi.org/10.1002/ejhf.42] [PMID: 24464626]
[24]
Ning, Y.; Cheng, Y.J.; Liu, L.J.; Sara, J.D.; Cao, Z.Y.; Zheng, W.P.; Zhang, T.S.; Han, H.J.; Yang, Z.Y.; Zhang, Y.; Wang, F.L.; Pan, R.Y.; Huang, J.L.; Wu, L.L.; Zhang, M.; Wei, Y.X. What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants. BMC Med., 2017, 15(1), 21.
[http://dx.doi.org/10.1186/s12916-017-0777-9] [PMID: 28148249]
[25]
Klein, I.; Ojamaa, K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med., 2001, 344(7), 501-509.
[http://dx.doi.org/10.1056/NEJM200102153440707] [PMID: 11172193]
[26]
Bielecka-Dabrowa, A.; Godoy, B.; Suzuki, T.; Banach, M.; von Haehling, S. Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function. Clin. Res. Cardiol., 2019, 108(3), 225-233.
[http://dx.doi.org/10.1007/s00392-018-1340-1] [PMID: 30091084]
[27]
Kahaly, G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid, 2000, 10(8), 665-679.
[http://dx.doi.org/10.1089/10507250050137743] [PMID: 11014311]
[28]
Sun, J.; Yao, L.; Fang, Y.; Yang, R.; Chen, Y.; Yang, K.; Tian, L. Relationship between Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Int. J. Endocrinol., 2017, 20178130796
[http://dx.doi.org/10.1155/2017/8130796] [PMID: 29081800]
[29]
Altamirano Ufion, A.; Zulfiqar, B.; Hassan, A.; Habibi, R.; Boddu, P. Subclinical Hypothyroidism and Its Association with Increased Cardiovascular Mortality. Cardiol. Res. Pract., 2017, 20177539735
[http://dx.doi.org/10.1155/2017/7539735] [PMID: 29170719]
[30]
Iacoviello, M.; Guida, P.; Guastamacchia, E.; Triggiani, V.; Forleo, C.; Catanzaro, R.; Cicala, M.; Basile, M.; Sorrentino, S.; Favale, S. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr. Pharm. Des., 2008, 14(26), 2686-2692.
[http://dx.doi.org/10.2174/138161208786264142] [PMID: 19006851]
[31]
Triggiani, V.; Angelo Giagulli, V.; De Pergola, G.; Licchelli, B.; Guastamacchia, E.; Iacoviello, M. Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure. Endocr. Metab. Immune Disord. Drug Targets, 2016, 16(1), 2-7.
[http://dx.doi.org/10.2174/1871530316666151218151319] [PMID: 26680772]
[32]
Gencer, B.; Collet, T.H.; Virgini, V.; Bauer, D.C.; Gussekloo, J.; Cappola, A.R.; Nanchen, D.; den Elzen, W.P.; Balmer, P.; Luben, R.N.; Iacoviello, M.; Triggiani, V.; Cornuz, J.; Newman, A.B.; Khaw, K.T.; Jukema, J.W.; Westendorp, R.G.; Vittinghoff, E.; Aujesky, D.; Rodondi, N. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation, 2012, 126(9), 1040-1049.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.096024] [PMID: 22821943]
[33]
Opasich, C.; Pacini, F.; Ambrosino, N.; Riccardi, P.G.; Febo, O.; Ferrari, R.; Cobelli, F.; Tavazzi, L. Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur. Heart J., 1996, 17(12), 1860-1866.
[http://dx.doi.org/10.1093/oxfordjournals.eurheartj.a014804] [PMID: 8960429]
[34]
Shanoudy, H.; Soliman, A.; Moe, S.; Hadian, D.; Veldhuis, J.D.; Iranmanesh, A.; Russell, D.C. Early manifestations of “sick euthyroid” syndrome in patients with compensated chronic heart failure. J. Card. Fail., 2001, 7(2), 146-152.
[http://dx.doi.org/10.1054/jcaf.2001.24665] [PMID: 11420766]
[35]
Ascheim, D.D.; Hryniewicz, K. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid, 2002, 12(6), 511-515.
[http://dx.doi.org/10.1089/105072502760143908] [PMID: 12165115]
[36]
Bartalena, L.; Bogazzi, F.; Brogioni, S.; Grasso, L.; Martino, E. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur. J. Endocrinol., 1998, 138(6), 603-614.
[http://dx.doi.org/10.1530/eje.0.1380603] [PMID: 9678522]
[37]
Barbesino, G. Thyroid Function Changes in the Elderly and Their Relationship to Cardiovascular Health: A Mini-Review. Gerontology, 2019, 65(1), 1-8.
[http://dx.doi.org/10.1159/000490911] [PMID: 30032140]
[38]
Galli, E.; Pingitore, A.; Iervasi, G. The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence. Heart Fail. Rev., 2010, 15(2), 155-169.
[http://dx.doi.org/10.1007/s10741-008-9126-6] [PMID: 19110971]
[39]
Pingitore, A.; Landi, P.; Taddei, M.C.; Ripoli, A.; L’Abbate, A.; Iervasi, G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am. J. Med., 2005, 118(2), 132-136.
[http://dx.doi.org/10.1016/j.amjmed.2004.07.052] [PMID: 15694896]
[40]
Rothberger, G.D.; Gadhvi, S.; Michelakis, N.; Kumar, A.; Calixte, R.; Shapiro, L.E. Usefulness of Serum Triiodothyronine (T3) to Predict Outcomes in Patients Hospitalized With Acute Heart Failure. Am. J. Cardiol., 2017, 119(4), 599-603.
[http://dx.doi.org/10.1016/j.amjcard.2016.10.045] [PMID: 28017303]
[41]
Chuang, C-P.; Jong, Y-S.; Wu, C-Y.; Lo, H-M. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure. Am. J. Cardiol., 2014, 113(5), 845-850.
[http://dx.doi.org/10.1016/j.amjcard.2013.11.039] [PMID: 24406111]
[42]
Frączek-Jucha, M. Selenium deficiency and the dynamics of changes of thyroid profile in patients with acute myocardial infarction and chronic heart failure.,
[http://dx.doi.org/10.33963/KP.14822]
[43]
Wajner, S.M.; Rohenkohl, H.C.; Serrano, T.; Maia, A.L. Sodium selenite supplementation does not fully restore oxidative stress-induced deiodinase dysfunction: Implications for the nonthyroidal illness syndrome. Redox Biol., 2015, 6, 436-445.
[http://dx.doi.org/10.1016/j.redox.2015.09.002] [PMID: 26402162]
[44]
Fraczek-Jucha, M.; Zbierska-Rubinkiewicz, K.; Kabat, M.; Plens, K.; Rychlak, R.; Nessler, J.; Gackowski, A. Low triiodothyronine syndrome and selenium deficiency - undervalued players in advanced heart failure? A single center pilot study. BMC Cardiovasc. Disord., 2019, 19(1), 105.
[http://dx.doi.org/10.1186/s12872-019-1076-5] [PMID: 31064347]
[45]
Forini, F.; Nicolini, G.; Iervasi, G. Mitochondria as key targets of cardioprotection in cardiac ischemic disease: role of thyroid hormone triiodothyronine. Int. J. Mol. Sci., 2015, 16(3), 6312-6336.
[http://dx.doi.org/10.3390/ijms16036312] [PMID: 25809607]
[46]
Morkin, E.; Pennock, G.D.; Raya, T.E.; Bahl, J.J.; Goldman, S. Development of a thyroid hormone analogue for the treatment of congestive heart failure. Thyroid, 1996, 6(5), 521-526.
[http://dx.doi.org/10.1089/thy.1996.6.521] [PMID: 8936682]
[47]
Wickenden, A.D.; Kaprielian, R.; You, X-M.; Backx, P.H. The thyroid hormone analog DITPA restores I(to) in rats after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2000, 278(4), H1105-H1116.
[http://dx.doi.org/10.1152/ajpheart.2000.278.4.H1105] [PMID: 10749704]
[48]
Pennock, G.D.; Spooner, P.H.; Summers, C.E.; Litwin, S.E. Prevention of abnormal sarcoplasmic reticulum calcium transport and protein expression in post-infarction heart failure using 3, 5-diiodothyropropionic acid (DITPA). J. Mol. Cell. Cardiol., 2000, 32(11), 1939-1953.
[http://dx.doi.org/10.1006/jmcc.2000.1225] [PMID: 11040100]
[49]
Maitra, N.; Adamson, C.; Greer, K.; Klewer, S.; Hoying, J.; Bahl, J.J.; Goldman, S.; Morkin, E. Regulation of gene expression in rats with heart failure treated with the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) and the combination of DITPA and captopril. J. Cardiovasc. Pharmacol., 2007, 50(5), 526-534.
[http://dx.doi.org/10.1097/FJC.0b013e318142bdf2] [PMID: 18030062]
[50]
Wang, X.; Zheng, W.; Christensen, L.P.; Tomanek, R.J. DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am. J. Physiol. Heart Circ. Physiol., 2003, 284(2), H613-H618.
[http://dx.doi.org/10.1152/ajpheart.00449.2002] [PMID: 12414442]
[51]
Zheng, W.; Weiss, R.M.; Wang, X.; Zhou, R.; Arlen, A.M.; Lei, L.; Lazartigues, E.; Tomanek, R.J. DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling. Am. J. Physiol. Heart Circ. Physiol., 2004, 286(5), H1994-H2000.
[http://dx.doi.org/10.1152/ajpheart.00991.2003] [PMID: 15072976]
[52]
Hamilton, M.A.; Stevenson, L.W.; Fonarow, G.C.; Steimle, A.; Goldhaber, J.I.; Child, J.S.; Chopra, I.J.; Moriguchi, J.D.; Hage, A. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am. J. Cardiol., 1998, 81(4), 443-447.
[http://dx.doi.org/10.1016/S0002-9149(97)00950-8] [PMID: 9485134]
[53]
Morkin, E.; Pennock, G.; Spooner, P.H.; Bahl, J.J.; Underhill Fox, K.; Goldman, S. Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology, 2002, 97(4), 218-225.
[http://dx.doi.org/10.1159/000063110] [PMID: 12145478]
[54]
Goldman, S.; McCarren, M.; Morkin, E.; Ladenson, P.W.; Edson, R.; Warren, S.; Ohm, J.; Thai, H.; Churby, L.; Barnhill, J.; O’Brien, T.; Anand, I.; Warner, A.; Hattler, B.; Dunlap, M.; Erikson, J.; Shih, M.C.; Lavori, P. DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation, 2009, 119(24), 3093-3100.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.834424] [PMID: 19506112]
[55]
Ladenson, P.W.; McCarren, M.; Morkin, E.; Edson, R.G.; Shih, M.C.; Warren, S.R.; Barnhill, J.G.; Churby, L.; Thai, H.; O’Brien, T.; Anand, I.; Warner, A.; Hattler, B.; Dunlap, M.; Erikson, J.; Goldman, S. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J. Clin. Endocrinol. Metab., 2010, 95(3), 1349-1354.
[http://dx.doi.org/10.1210/jc.2009-1209] [PMID: 20080837]
[56]
Pingitore, A.; Galli, E.; Barison, A.; Iervasi, A.; Scarlattini, M.; Nucci, D.; L’abbate, A.; Mariotti, R.; Iervasi, G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab., 2008, 93(4), 1351-1358.
[http://dx.doi.org/10.1210/jc.2007-2210] [PMID: 18171701]
[57]
Holmager, P.; Schmidt, U.; Mark, P.; Andersen, U.; Dominguez, H.; Raymond, I.; Zerahn, B.; Nygaard, B.; Kistorp, C.; Faber, J. Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study. Clin. Endocrinol. (Oxf.), 2015, 83(6), 931-937.
[http://dx.doi.org/10.1111/cen.12648] [PMID: 25359424]
[58]
Amin, A.; Chitsazan, M.; Taghavi, S.; Ardeshiri, M. Effects of triiodothyronine replacement therapy in patients with chronic stable heart failure and low-triiodothyronine syndrome: a randomized, double-blind, placebo-controlled study. ESC Heart Fail., 2015, 2(1), 5-11.
[http://dx.doi.org/10.1002/ehf2.12025] [PMID: 28834641]
[59]
Pingitore, A.; Mastorci, F.; Piaggi, P.; Aquaro, G.D.; Molinaro, S.; Ravani, M.; De Caterina, A.; Trianni, G.; Ndreu, R.; Berti, S.; Vassalle, C.; Iervasi, G. Usefulness of Triiodothyronine Replacement Therapy in Patients With ST Elevation Myocardial Infarction and Borderline/Reduced Triiodothyronine Levels (from the THIRST Study). Am. J. Cardiol., 2019, 123(6), 905-912.
[http://dx.doi.org/10.1016/j.amjcard.2018.12.020] [PMID: 30638544]
[60]
Gheorghiade, M.; Colucci, W.S.; Swedberg, K. β-blockers in chronic heart failure. Circulation, 2003, 107(12), 1570-1575.
[http://dx.doi.org/10.1161/01.CIR.0000065187.80707.18] [PMID: 12668487]
[61]
Tai, C.; Gan, T.; Zou, L.; Sun, Y.; Zhang, Y.; Chen, W.; Li, J.; Zhang, J.; Xu, Y.; Lu, H.; Xu, D. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 2017, 17(1), 257.
[http://dx.doi.org/10.1186/s12872-017-0686-z] [PMID: 28982370]
[62]
Solomon, S.D.; Claggett, B.; McMurray, J.J.V.; Hernandez, A.F.; Fonarow, G.C. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Eur. J. Heart Fail., 2016, 18(10), 1238-1243.
[http://dx.doi.org/10.1002/ejhf.603] [PMID: 27364182]
[63]
Arcopinto, M.; Salzano, A.; Isgaard, J.; Cittadini, A. Hormone replacement therapy in heart failure. Curr. Opin. Cardiol., 2015, 30(3), 277-284.
[http://dx.doi.org/10.1097/HCO.0000000000000166] [PMID: 25807222]
[64]
Stott, D.J.; Gussekloo, J.; Kearney, P.M.; Rodondi, N.; Westendorp, R.G.; Mooijaart, S.; Kean, S.; Quinn, T.J.; Sattar, N.; Hendry, K.; Du Puy, R.; Den Elzen, W.P.; Poortvliet, R.K.; Smit, J.W.; Jukema, J.W.; Dekkers, O.M.; Blum, M.; Collet, T.H.; McCarthy, V.; Hurley, C.; Byrne, S.; Browne, J.; Watt, T.; Bauer, D.; Ford, I. Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST). BMC Endocr. Disord., 2017, 17(1), 6.
[http://dx.doi.org/10.1186/s12902-017-0156-8] [PMID: 28158982]
[65]
Bossone, E.; Arcopinto, M.; Iacoviello, M.; Triggiani, V.; Cacciatore, F.; Maiello, C.; Limongelli, G.; Masarone, D.; Perticone, F.; Sciacqua, A.; Perrone-Filardi, P.; Mancini, A.; Volterrani, M.; Vriz, O.; Castello, R.; Passantino, A.; Campo, M.; Modesti, P.A.; De Giorgi, A.; Monte, I.; Puzzo, A.; Ballotta, A.; Caliendo, L.; D’Assante, R.; Marra, A.M.; Salzano, A.; Suzuki, T.; Cittadini, A. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry. Intern. Emerg. Med., 2018, 13(5), 661-671.
[http://dx.doi.org/10.1007/s11739-018-1844-8] [PMID: 29619769]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 5
Year: 2020
Published on: 31 May, 2020
Page: [646 - 653]
Pages: 8
DOI: 10.2174/1871530319666191119112950
Price: $65

Article Metrics

PDF: 26
HTML: 2